TPST — Tempest Therapeutics Share News
0.000.00%
Last trade - 00:00Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T
Brief: Tempest Therapeutics Appoints Drake Richey And John Yee To Board Of Directors
Brief: Tempest Therapeutics Says Nicholas Maestas Resigns As CFO Effective June 5
Tempest Therapeutics Q1 net loss widens on asset acquisition costs
Brief: Tempest Reports Year End 2025 Financial Results And Provides Business Update
U.S. STOCKS ON THE MOVE-Micron, McDonald's, Generac
U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Tempest Therapeutics rises on partner‑funded plan for new cancer drugs
Brief: Tempest Lays Out Strategic Plan To Advance Recently Acquired Dual-Targeting Car-T Assets
Brief: Tempest Announces Closing Of Strategic Acquisition Of Dual-Targeting Car-T Assets
Brief: Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules
Brief: Tempest Announces Strategic Acquisition Of New Dual-Car T Programs From Factor With Simultaneous Runway Extension Projected To Mid 2027
Brief: Tempest Therapeutics Q3 EPS USD -0.79
Tempest Therapeutics Q3 net loss narrows as costs drop, continues strategic alternatives process
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary